VantroMarket Overview
← All markets
Health Market Overview

Ireland

Last updated: November 2026
Regulatory Body
Health Products Regulatory Authority (HPRA)
Typical Timeline
30-210 days depending on procedure type and product category
Regulatory Overview

The Health Products Regulatory Authority (HPRA) is the competent authority responsible for regulating medicines, medical devices, in vitro diagnostics, and related health products in Ireland. The primary legislative framework includes the Irish Medicines Board (Establishment) Acts 1995-2006, the Medicinal Products Regulations (transposing EU Directives and Regulations), and EU Regulations such as Regulation (EU) 2017/745 (MDR) for medical devices and Regulation (EU) 2017/746 (IVDR) for in vitro diagnostics. As an EU member state, Ireland participates fully in centralised, decentralised, and mutual recognition procedures administered through the European Medicines Agency (EMA), meaning that products approved via the centralised procedure are automatically valid in Ireland. For nationally authorised products, the HPRA conducts its own review process, while also fulfilling its role as a reference or concerned member state in decentralised and mutual recognition procedures.

Submission requirements align with EU standards, with the Common Technical Document (CTD) format being mandatory for pharmaceutical marketing authorisation applications. A locally registered Legal Entity or EU-based Qualified Person for Pharmacovigilance (QPPV) must be designated, along with an EU Representative for medical device manufacturers based outside the European Economic Area. Ireland adopted EU MDR and IVDR timelines, including the phased transition deadlines extended by the European Commission in 2023 for legacy medical devices and IVDs. Recent reforms have focused on strengthening pharmacovigilance obligations, expanding the HPRA's role in digital health product classification guidance, and aligning national enforcement with evolving EU regulatory science frameworks. The HPRA also participates in the European network of competent authorities and contributes to joint scientific assessments under Health Technology Assessment (HTA) Regulation (EU) 2021/2282.

Procurement Overview

Public procurement of health products in Ireland is primarily coordinated through the Health Service Executive (HSE), the statutory body responsible for delivering all public health and social care services in Ireland. The HSE operates a centralised procurement function through HSE Health Business Services (HBS) Procurement, which manages national contracts and framework agreements for pharmaceuticals, medical devices, diagnostics, and digital health solutions. The National Centre for Pharmacoeconomics (NCPE) conducts health technology assessments and cost-effectiveness evaluations that inform reimbursement decisions for pharmaceuticals under the GMS (General Medical Services) and other community drug schemes. Reimbursement decisions are made by the HSE following NCPE recommendations and price negotiations with manufacturers, governed by the Health (Pricing and Supply of Medical Goods) Act 2013. Medical devices and diagnostics procured at hospital level are subject to EU public procurement rules as transposed into Irish law via the European Union (Award of Public Authority Contracts) Regulations 2016, with tenders published on the eTenders national platform.

Ireland does not have a significant parallel private-sector or donor-funded procurement channel for health products in the manner seen in lower-income markets; the dominant channel is the publicly funded HSE system, supplemented by private health insurers such as VHI, Laya Healthcare, and Irish Life Health for privately delivered care. There are no active UNICEF, Global Fund, USAID, or Gavi procurement channels in Ireland given its high-income status. However, local and EU-level policy increasingly encourages procurement practices that consider supply chain resilience, sustainability criteria, and innovation partnerships, particularly for digital health and diagnostics. The HSE has developed a dedicated Digital Transformation programme and national digital health frameworks that influence procurement priorities for health IT and digital health solutions, with vendors typically required to demonstrate interoperability with national systems such as the Individual Health Identifier (IHI) infrastructure and compliance with applicable data protection legislation under the GDPR.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Ireland →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.